"Dosing the first subjects with the most advanced oral tablet COVID-19 vaccine candidate marks another important step forward toward developing a transformative solution to the SARS-CoV-2 global pandemic," said Andrei Floroiu, Vaxart's Chief Executive Officer. portion of the trial will be a randomized open-label dose and age escalation lead-in segment in naïve and previously vaccinated subjects, to be followed by an international placebo-controlled efficacy trial. The full data set from the U.S. trial will be followed by an international trial involving a larger pool of subjects. Vaxart expects to enroll 96 subjects at four sites in the United States in the first part of its Phase II trial. (NASDAQ: VXRT) today announced that it has dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial, the only Phase II trial of an oral tablet COVID-19 vaccine underway in the world. SOUTH SAN FRANCISCO, CA, USA I OctoI Vaxart, Inc. Vaxart Now Operates Two Manufacturing Facilities To Support Timely Progress of Multiple Clinical Programs Study Will Evaluate Safety, Immunogenicity and Efficacy of the Only Oral Tablet COVID-19 Vaccine in Phase II
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |